Accurate differentiation between benign and malignant focal liver lesions (FLLs) is crucial for patient management, influencing treatment strategies and reducing unnecessary interventions. Magnetic resonance imaging (MRI) with contrast agents is a preferred diagnostic tool due to its high-resolution imaging and non-invasive nature. Gadobenate dimeglumine and gadoxetate disodium are two hepatobiliary contrast agents widely used for liver MRI. A recent study published in European Radiology Experimental examines their comparative efficacy in differentiating and diagnosing FLLs based on intraindividual crossover studies, highlighting their respective advantages and limitations.
Diagnostic Performance of Gadobenate and Gadoxetate
Gadobenate demonstrated superior diagnostic performance over gadoxetate across key parameters such as sensitivity, specificity and accuracy in differentiating malignant from benign liver lesions. The study found that sensitivity and specificity values for gadobenate ranged from 91.6% to 99.1% and 87.5% to 90.5%, respectively, while gadoxetate's values were slightly lower at 86.0% to 91.6% and 79.7% to 83.6%. Notably, gadobenate showed a significantly higher inter-reader agreement (κ= 0.91) compared to gadoxetate (κ= 0.72), suggesting greater reliability in diagnostic consistency. This improved performance is attributed to gadobenate’s superior dynamic phase imaging, which enhances lesion characterisation and reduces diagnostic uncertainty.
Additionally, the study highlighted that gadobenate's performance was particularly advantageous for two out of three radiologists, who demonstrated significantly greater accuracy and confidence when assessing lesion nature and classification. This suggests that the agent’s imaging properties contribute to more reliable interpretations, potentially leading to improved patient outcomes by reducing misdiagnoses and unnecessary follow-ups.
Impact on Lesion Detection and Classification
The ability to detect and classify liver lesions accurately influences subsequent clinical decisions. The study revealed that gadobenate led to fewer missed lesions compared to gadoxetate, particularly in detecting small hemangiomas and dysplastic nodules. Among malignant lesions, hepatocellular carcinoma (HCC) was more accurately classified with gadobenate, whereas gadoxetate showed higher rates of misclassification, often confusing hemangiomas with metastases due to pseudo-washout effects during the transitional phase. This pseudo-washout effect occurs when contrast uptake in the normal liver tissue exceeds that of hypervascular lesions, leading to a misleading appearance that can complicate accurate lesion assessment.
Furthermore, gadobenate’s performance in delineating cholangiocellular carcinoma (CC) was enhanced by its late-phase imaging capability, which better captured fibrotic components, a key feature distinguishing CC from other hepatic malignancies. This advantage allows for more confident diagnoses and can assist in formulating more precise treatment plans. The inter-reader agreement was also notably better with gadobenate, reinforcing its consistency and reliability in clinical settings.
Clinical Implications and Confidence in Diagnosis
Gadobenate’s enhanced diagnostic confidence led to fewer differential diagnoses, allowing for more precise lesion characterisation. The study reported that two of the three radiologists achieved significantly greater confidence in assigning specific lesion diagnoses with gadobenate. Confidence in a diagnosis is critical in radiology, as it directly impacts clinical decision-making, reducing the likelihood of unnecessary procedures and ensuring timely and appropriate treatment.
Recommended Read : MRI Texture Analysis in Liver Biopsy Complications
The reduced need for follow-up examinations and biopsies has significant implications for patient management, reducing costs and expediting treatment decisions. This efficiency is particularly valuable in resource-limited healthcare systems where reducing the burden of unnecessary procedures can improve overall patient care. Moreover, the ability to establish a clearer diagnosis early in the clinical workflow supports better patient counselling and management, ensuring that treatment pathways are optimised based on the most accurate information available.
The study also noted that while gadoxetate is taken up by hepatocytes more rapidly, leading to earlier hepatobiliary phase imaging, this advantage is offset by its limitations in dynamic phase imaging. In contrast, gadobenate’s longer retention allows for a more comprehensive assessment across different imaging phases, contributing to its overall superior performance.
This comparative analysis underscores the superior performance of gadobenate dimeglumine over gadoxetate disodium for liver MRI in characterising FLLs. Gadobenate’s advantages include higher sensitivity and specificity, improved lesion detection and greater diagnostic confidence. Its ability to enhance lesion characterisation with fewer misdiagnoses and reduced need for additional diagnostic procedures makes it a preferable choice in many clinical settings.
Given the significant impact on diagnostic accuracy and patient management, the study suggests that gadobenate may be a more effective contrast agent for differentiating benign from malignant liver lesions. Further studies with a broader range of FLL types and patient populations could reinforce these conclusions and support optimised MRI protocols for liver imaging, ensuring the most reliable and effective diagnostic strategies are employed.
Source: European Radiology Experimental
Image Credit: Freepik
References:
Tang W, Xiao Y, Kuang S et al. (2025) Intraindividual crossover comparison of gadobenate dimeglumine-enhanced and gadoxetate disodium-enhanced MRI for characterizing focal liver lesions. Eur Radiol Exp, 9:23.
Image: https://m
